REGENXBIO Inc. (RGNX)
NASDAQ: RGNX · Real-Time Price · USD
8.74
+0.12 (1.39%)
Jul 3, 2025, 1:00 PM - Market closed
REGENXBIO Employees
REGENXBIO had 353 employees as of December 31, 2024. The number of employees increased by 9 or 2.62% compared to the previous year.
Employees
353
Change (1Y)
9
Growth (1Y)
2.62%
Revenue / Employee
$443,960
Profits / Employee
-$446,711
Market Cap
440.40M
Employees Chart
Related Stocks
| Company Name | Employees |
|---|---|
| UnitedHealth Group | 400,000 |
| Johnson & Johnson | 138,100 |
| Thermo Fisher Scientific | 125,000 |
| Abbott Laboratories | 114,000 |
| AstraZeneca | 94,300 |
| Novo Nordisk | 77,349 |
| Novartis AG | 75,883 |
| Merck & Co. | 75,000 |
RGNX News
- 4 weeks ago - Regenxbio's RGX-121 Could Become The New Standard Of Care In Hunter Syndrome - Seeking Alpha
- 4 weeks ago - Early Wins: RegenXBio's Gene Therapy Helps Duchenne Patients Walk Stronger, Longer - Benzinga
- 4 weeks ago - REGENXBIO REPORTS NEW POSITIVE FUNCTIONAL DATA FROM PHASE I/II AFFINITY DUCHENNE® TRIAL OF RGX-202 - PRNewsWire
- 4 weeks ago - REGENXBIO to Host Webcast Discussing Interim Functional Data from the Phase I/II AFFINITY DUCHENNE® Trial of RGX-202 - PRNewsWire
- 6 weeks ago - REGENXBIO Announces Strategic Royalty Monetization Agreement for Up to $250 Million - PRNewsWire
- 7 weeks ago - FDA Accepts Biologics License Application for Mucopolysaccharidosis II Treatment - PRNewsWire
- 7 weeks ago - REGENXBIO Inc. (RGNX) Q1 2025 Earnings Call Transcript - Seeking Alpha
- 7 weeks ago - REGENXBIO Announces FDA Acceptance and Priority Review of the BLA for RGX-121 for MPS II - PRNewsWire